Gianni Caterina, Palleschi Michela, Schepisi Giuseppe, Casadei Chiara, Bleve Sara, Merloni Filippo, Sirico Marianna, Sarti Samanta, Cecconetto Lorenzo, Di Menna Giandomenico, Schettini Francesco, De Giorgi Ugo
Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
Front Oncol. 2022 Aug 8;12:882896. doi: 10.3389/fonc.2022.882896. eCollection 2022.
Adaptive and innate immune cells play a crucial role as regulators of cancer development. Inflammatory cells in blood flow seem to be involved in pro-tumor activities and contribute to breast cancer progression. Circulating lymphocyte ratios such as the platelet-lymphocytes ratio (PLR), the monocyte-lymphocyte ratio (MLR) and the neutrophil-lymphocyte ratio (NLR) are new reproducible, routinely feasible and cheap biomarkers of immune response. These indexes have been correlated to prognosis in many solid tumors and there is growing evidence on their clinical applicability as independent prognostic markers also for breast cancer. In this review we give an overview of the possible value of lymphocytic indexes in advanced breast cancer prognosis and prediction of outcome. Furthermore, targeting the immune system appear to be a promising therapeutic strategy for breast cancer, especially macrophage-targeted therapies. Herein we present an overview of the ongoing clinical trials testing systemic inflammatory cells as therapeutic targets in breast cancer.
适应性免疫细胞和先天性免疫细胞作为癌症发展的调节因子发挥着关键作用。血流中的炎症细胞似乎参与促肿瘤活动，并促进乳腺癌进展。循环淋巴细胞比率，如血小板-淋巴细胞比率（PLR）、单核细胞-淋巴细胞比率（MLR）和中性粒细胞-淋巴细胞比率（NLR），是免疫反应新的可重复、常规可行且廉价的生物标志物。这些指标已与多种实体瘤的预后相关，并且越来越多的证据表明它们作为乳腺癌独立预后标志物的临床适用性。在本综述中，我们概述了淋巴细胞指标在晚期乳腺癌预后和结局预测中的可能价值。此外，靶向免疫系统似乎是乳腺癌一种有前景的治疗策略，尤其是巨噬细胞靶向治疗。在此，我们概述了正在进行的将全身炎症细胞作为乳腺癌治疗靶点的临床试验。
